Trimetazidine shortens QTc interval in patients with ischemic heart failure

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 1, 2010, Pages 31-36

  Zemljic, Gregor ^a   Bunc, Matjaz ^a   Vrtovec, Bojan ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Heart failure; QTc interval; Trimetazidine

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; TRIMETAZIDINE;

ADULT; AGED; ALLOPATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT INTERVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOGRAPHY; ELECTROCARDIOGRAM PATTERN; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; REGRESSION ANALYSIS; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 76649128989     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248409354601     Document Type: Article

References (50)

1. Kantor PF, Lucien A., Kozak R., Lopaschuk GD The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000 ; 86 (5). 580-588.
2. Sellier P., Audouin P., Payen B., Corona P., Duong TC, Ourbak P. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol. 1987 ; 33 (2). 205-207.
3. Timour Q., Harpney C., Francoise D., Faucon C. Is the antianginal action of trimetazidine independent of hemodynamic changes. Cardiovasc Drugs Ther. 1991 ; 5 (6). 1043-1044.
4. Fragasso G., Palloshi A., Puccetti P., et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006 ; 48 (5). 992-998.
5. Metra M., Ponikowski P., Dickstein K., et al. Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure. A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007 ; 9 (6-7). 684-694.
6. Bertomeu-Gonzalez V., Bouzas-Mosquera A., Kaski JC Role of trimetazidine in management of ischemic cardiomyopathy. Am J Cardiol. 2006 ; 98 (5A). 19J - 24J.
7. Boccalandro F., Velaso A., Thomas C., Richards B., Radovancevic B. Relations among heart failure severity, left ventricular loading conditions, repolarization length in advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2003 ; 92 (5). 544-547.
8. Vrtovec B., Delgado R., Zewail A., Thomas CD, Richartz BM, Radovancevic B. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation. 2003 ; 107 (13). 1764-1769.
9. Vrtovec B., Yazdanbakhsh AP, Pintar T., Collard CD, Gregoric ID, Radovancevic B. QTc interval prolongation predicts postoperative mortality in heart failure patients undergoing surgical revascularization. Tex Heart Inst J. 2006 ; 33 (1). 3-8.
10. Elming H., Brendorp B., Kober L., Sahebzadah N., Torp-Petersen C. QTc interval in the assessment of cardiac risk. Card Electrophysiol Rev. 2002 ; 6 (3). 289-294.
11. Peters RW, Byington RP, Barker A., Yusuf S. Prognostic value of prolonged ventricular repolarization following myocardial infarction: the BHAT experience. The BHAT Study Group. J Clin Epidemiol. 1990 ; 43 (2). 167-172.
12. Rossing P., Breum L., Major-Pedersen A., et al. Prolonged QTc interval predicts mortality in patients with type 1 diabetes mellitus. Diabet Med. 2001 ; 18 (3). 199-205.
13. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006 ; 47 (2). 362-367.
14. Schouten EG, Dekker JM, Meppelink P., Kok FJ, Vandenbroucke JP, Pool J. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation. 1991 ; 84 (4). 1516-1523.
15. Kiyosue T., Nakamura S., Arita M. Effects of trimetazidine on action potentials and membrane currents of guinea-pig ventricular myocytes. J Mol Cell Cardiol. 1986 ; 18 (12). 1301-1311.
16. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005 ; 46 (6). 1-82. Erratum in: J Am Coll Cardiol. 2006 ; 47 (7). 1503-1505.
17. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005 ; 26 (11). 1115-1140.
18. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation. 1998 ; 98 (18). 1928-1936. (Pubitemid 28509291)
19. Antzelevitch C., Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002 ; 17 (1). 43-51. (Pubitemid 34073163)
20. Kjaer A., Hesse B. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clin Physiol. 2001 ; 21 (6). 661-672. (Pubitemid 33120896)
21. Berton G., Cordiano R., Palmieri R., Pianca S., Pagliara V., Palatini P. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J. 2003 ; 145 (6). 1094-1101.
22. Alonso-Martinez JL, Llorente-Diez B., Echegaray-Agara M., Olaz-Preciado F., Urbieta-Echezarreta M., González-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail. 2002 ; 4 (3). 331-336.
23. Liuzzo G., Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994 ; 331 (7). 417-424.
24. Libby P., Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002 ; 105 (9). 1135-1143.
25. Maseri A. Inflammation, atherosclerosis, and ischemic events: exploring the hidden side of the moon. N Engl J Med. 1997 ; 336 (14). 1014-1016.
26. Avanzas P., Arroyo-Espliguero R., Cosin-Sales J., Quiles J., Zouridakis E., Kaski JC Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis. 2004 ; 175 (1). 151-157.
27. Arroyo-Espliguero R., Avanzas P., Cosin-Sales J., Aldama G., Pizzi C., Kaski JC C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. 2004 ; 25 (5). 401-408. (Pubitemid 38391522)
28. Zouridakis E., Avanzas P., Arroyo-Espliguero R., Fredericks S., Kaski JC Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation. 2004 ; 110 (13). 1747-1753.
29. Ihling C., Szombathy T., Bohrmann B., Brockhaus M., Schaefer HE, Loeffler BM Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation. 2001 ; 104 (8). 864-869.
30. Ihling C., Bohrmann B., Schaefer HE, Technau-Ihling K., Loeffler BM Endothelin-1 and endothelin converting enzyme-1 in human atherosclerosis-novel targets for pharmacotherapy in atherosclerosis. Curr Vasc Pharmacol. 2004 ; 2 (3). 249-258.
31. Suresh DP, Lamba S., Abraham WT New developments in heart failure: role of endothelin and the use of endothelin receptor antagonists. J Card Fail. 2000 ; 6 (4). 359-368.
32. Konstam MA, DeNofrio D. Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development. Circulation. 2004 ; 109 (2). 143-145.
33. Ertl G., Bauersachs J. Endothelin receptor antagonists in heart failure: current status and future directions. Drugs. 2004 ; 64 (10). 1029-1040.
34. Posa I., Horkay F., Seres L., et al. Effects of Experimental Diabetes on Endothelin-induced Ventricular Arrhythmias in Dogs. J Cardiovasc Pharmacol. 2004 ; 44 (suppl 1). S380 - S382.
35. Toth M., Solti F., Merkely B., et al. Bradycardia increases the arrhythmogenic effect of endothelin. J Cardiovasc Pharmacol. 1998 ; 31 (suppl 1). S431 - S433.
36. Raghunandan DS, Desai N., Mallavarapu M., Berger RD, Yeragani VK Increased beat-to-beat QT variability in patients with congestive cardiac failure. Indian Heart J. 2005 ; 57 (2). 138-142.
37. Kay L., Finelli C., Aussedat J., Guarnieri C., Rossi A. Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: effects on the energy state and mitochondrial function. Am J Cardiol. 1995 ; 76 (6). 45B - 49B.
38. Fantini E., Demaison L., Sentex E., Grynberg A., Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol. 1994 ; 26 (8). 949-958.
39. Lavanchy N., Martin J., Rossi A. Anti-ischemia effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther. 1987 ; 286 (1). 97-110.
40. Fragasso G., Perseghin G., De Cobelli F., et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006 ; 27 (8). 942-948.
41. Lagadic-Gossmann D., Le Prigent K., Feuvray D. Effects of trimetazidine on phi in the rat isolated ventricular myocyte. Br J Pharmacol. 1996 ; 117 (5). 831-838. (Pubitemid 26075960)
42. Renaud JF Internal pH, Na, and Ca regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther. 1988 ; 1 (6). 677-686.
43. Maridonneau-Parini I., Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol. 1985 ; 20 (2). 148-151.
44. Birand A., Kudaiberdieva GZ, Batyraliev TA, Akgul F., Usal A. Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology. 1997 ; 48 (5). 413-422.
45. Ulgen MS, Akdemir O., Toprak N. The effects of trimetazidine on heart rate variability and signal-averaged electrocardiography in early period of acute myocardial infarction. Int J Cardiol. 2001 ; 77 (2-3). 255-262. (Pubitemid 32162118)
46. Di Napoli P., Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005 ; 91 (2). 161-165.
47. Williams FM, Tanda K., Kus M., Williams TJ Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol. 1993 ; 22 (6). 828-833.
48. Tritto I., Wang P., Kuppusamy P., Giraldez R., Zweier JL, Ambrosio G. The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury. J Cardiovasc Pharmacol. 2005 ; 46 (1). 89-98.
49. Fragasso G., Piatti PM, Monti L., et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003 ; 146 (5). E18 - E25.
50. Monti LD, Setola E., Fragasso G., et al. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J Physiol Endocrinol Metab. 2006 ; 290 (1). E54 - E59.